Key Drivers
- High gross margin
- FY net loss
- Q4 profitability rebound
AIAI Summary
LivaNova appears to be a nascent, conditional recovery—strong unit economics and recent FCF/GAAP-positive quarters shift it from “distressed” to “execution-dependent growth,” so investors should require several consecutive quarters of sustained GAAP profitability and FCF at or above ~$150–200M (and a reclaim of the 21‑day MA / $70 resistance without breaking $58.5 support) before fully re-rating the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •FY net loss
- •Q4 profitability rebound
LIVN pairs robust gross margins and solid cash/liquidity with heavy operating spend and large intangibles that produced a FY net loss and negative returns despite a profitable Q4 rebound.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •Short-term support
- •Series of lower highs
LIVN is in a short-term downtrend over the last month—trading below its last month simple moving average after sliding ~10–12% from a late‑Feb peak, holding short-term support at $58.46 with resistance near $70–$71 that must be reclaimed for bullish momentum.
~10–12% decline from late‑Feb peak and failure to re-test $70–$71, increasing downside risk
Sentiment & News
Key News Insights:
- •Earnings beat
- •Institutional inflows
- •FDA PMA
LivaNova beat Q4/2025 revenue and earnings, issued 2026 guidance, saw sizable institutional buying and won FDA PMA for the aura6000—all supporting fundamentals despite recent share weakness.
Strong results, growing ownership and regulatory approval should support medium-term upside for the stock, though short-term volatility may continue
Similar Companies in Healthcare
Other companies in the same sector with AI ratings